Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
about
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentEvaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingMeta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisRisk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.The adverse effects of sorafenib in patients with advanced cancers.Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.Renal effects of targeted anticancer therapies.PharmGKB summary: sorafenib pathways.Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.Hypertension in malignancy-an underappreciated problem.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
P2860
Q26782585-DC961F2B-A314-430D-BCF9-04ED438FB8F2Q26783895-B4040B98-9A30-4A42-A64B-EFC77240E2B9Q30249335-FE1F1AFD-6A9C-499A-A1B4-4F218CAFDDC7Q33564645-E39A24B8-91AA-49A5-B8D3-37BB5637D2F6Q34943606-88B8DD9B-B9CB-4BC4-B7B1-896368C2B1D6Q35118673-D903E371-EE33-4212-AB69-C9AA3AD1C1ECQ38154815-26CFD192-9745-42D6-8CA6-29A5481F55F8Q38184936-BADA8A9E-3283-40B9-9DBA-2E4B10FC99C8Q38267043-D870AFB8-AF36-4B6F-81EA-0D22CBA59B04Q38286308-14BF7FB1-4C5F-491A-895D-4FC603317857Q38312035-7D6F4300-190A-429F-B39D-411F11A9703BQ38367168-82EFAE4A-BC2B-4F17-9699-08E2758643B3Q38864682-87B96DFB-9AD6-4601-8A42-539F432E2F20Q42359608-6A275CD5-8AE5-4F25-A931-B0123D6AD9B8Q50512896-4BF6AD34-16D6-452C-91B1-B9DF94BFB6DAQ52723478-3AC35A05-C6F0-4C0D-9064-79E238A6944AQ53142244-B54EF26F-50A0-420C-8AB4-FD0A0217E067Q55071881-801900E6-718B-4745-B9C3-43DD97F90C42Q57057499-8D5A7B56-92D9-4A2C-8AC8-D1589EA88705
P2860
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Risk of hypertension in cancer ...... atic review and meta-analysis.
@en
type
label
Risk of hypertension in cancer ...... atic review and meta-analysis.
@en
prefLabel
Risk of hypertension in cancer ...... atic review and meta-analysis.
@en
P2093
P2860
P356
P1476
Risk of hypertension in cancer ...... atic review and meta-analysis.
@en
P2093
P2860
P2888
P304
P356
10.1038/JHH.2013.30
P577
2013-05-02T00:00:00Z
P5875
P6179
1012376760